New evidence
In an open-label trial of 874 pregnant women, 200 mg/day lactoferrin was linked to 75% fewer asymptomatic bacteriuria episodes — but the lack of blinding and narrow population demand caution.
This is the first solid randomized trial on lactoferrin for urinary tract infections, but it was open-label (no placebo) and tested only in pregnant Egyptian women with recurrent UTIs, so the results may not apply to other groups and need replication.
Pregnant women with a history of recurrent UTIs who took 200 mg/day of lactoferrin had far fewer episodes of asymptomatic bacteriuria (bacteria in urine without symptoms) compared to those who didn't — 33 episodes versus 131 over six months. However, the study was not blinded (everyone knew who got the supplement), and the same trial found no effect on the more serious kidney infection pyelonephritis, so the benefit appears limited to milder forms of infection.
Where this fits in the evidence
This is among the first studies we've indexed on Lactoferrin for Reduced Asymptomatic Bacteriuria Episode — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- n = 874
- 2025-04-23
- BMC urology
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.